Ganguli R, Brar J S
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, PA 15213-2593, USA.
Psychopharmacol Bull. 1998;34(1):83-7.
The effects of the availability of risperidone and olanzapine on the indications for which clozapine is prescribed (treatment-resistance, treatment-intolerance, and/or negative symptoms) were examined for 252 patients with schizophrenia who began treatment at our hospital between June 1990 and June 1997. There were no statistical differences in the indications for clozapine treatment before and after the availability of either risperidone or olanzapine. Furthermore, there were no significant differences in the frequencies of the indications in subgroups of patients who had previously received a trial with risperidone or olanzapine, as compared with the remaining patients. The indications for clozapine appear to have been unaffected by the advent of risperidone and olanzapine; however, we noted a decrease in the absolute number of patients starting clozapine after risperidone became available. More recently, the majority of patients referred for treatment with clozapine had received previous trials with risperidone or olanzapine.
对1990年6月至1997年6月间在我院开始治疗的252例精神分裂症患者，研究了利培酮和奥氮平的可获得性对氯氮平处方适应证（治疗抵抗、治疗不耐受和/或阴性症状）的影响。在利培酮或奥氮平可获得之前和之后，氯氮平治疗的适应证没有统计学差异。此外，与其余患者相比，先前接受过利培酮或奥氮平试验的患者亚组中，适应证的频率也没有显著差异。氯氮平的适应证似乎未受利培酮和奥氮平出现的影响；然而，我们注意到利培酮可获得后开始使用氯氮平的患者绝对数量有所减少。最近，大多数被转诊接受氯氮平治疗的患者之前都接受过利培酮或奥氮平的试验。
